---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-098860"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:30:12.687471+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PepGen appoints Paul Streck, M.D., MBA as EVP, Head of Research & Development

## Summary
- Appoints Paul Streck, M.D., MBA as EVP, Head of R&D effective immediately, joining PepGen Executive Team.
- Streck brings >20 yrs drug development experience; previously CMO at Albireo, Arena, Alder, Insmed, and roles at GSK, Shire, Amgen.
- His accomplishments include five IND approvals, six global regulatory launches, nine commercial product launches.
- CEO James McArthur cites Streck's value as PepGen advances four active clinical trials and preclinical pipeline.

## SEC filing metadata
- accession: 0000950170-24-098860
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024098860/0000950170-24-098860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024098860/pepg-20240820.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-098860
- JSON: https://secwatch.observer/filing/0000950170-24-098860.json
- Plain text: https://secwatch.observer/filing/0000950170-24-098860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.